News
RCEL
11.84
+2.25%
0.26
Avita Medical’s PermeaDerm Trial Completion: What It Means for RCEL Investors
TipRanks · 3d ago
Avita Medical’s Cohealyx Trial Completion Puts New Focus on Advanced Wound Care
TipRanks · 3d ago
Weekly Report: what happened at RCEL last week (0914-0918)?
Weekly Report · 6d ago
Wall Street Analysts Are Bullish on Top Healthcare Picks
TipRanks · 09/18 08:30
Small-cap stocks with strong momentum grades and triple-digit YTD gains
Seeking Alpha · 09/17 13:55
Weekly Report: what happened at RCEL last week (0907-0911)?
Weekly Report · 09/14 09:17
Weekly Report: what happened at RCEL last week (0831-0904)?
Weekly Report · 09/07 09:16
6 Biotech Stocks In Focus: Modular Medical, Galmed, Pro-Dex, Connect Biopharma & More
NASDAQ · 09/04 02:47
Quant Check: Top- and bottom-rated small-cap healthcare stocks post-earnings
Seeking Alpha · 09/01 14:25
Weekly Report: what happened at RCEL last week (0824-0828)?
Weekly Report · 08/31 09:17
Avita Medical Is Maintained at Buy by Lake Street
Dow Jones · 08/28 15:28
Avita Medical Inc. (RCEL) is a Great Momentum Stock: Should You Buy?
NASDAQ · 08/24 16:00
AVITA Medical: Favorable Reimbursements For Skin Wound Care
Seeking Alpha · 08/24 12:30
Weekly Report: what happened at RCEL last week (0817-0821)?
Weekly Report · 08/24 09:17
Avita Medical Is Maintained at Buy by TD Cowen
Dow Jones · 08/19 15:20
TD Cowen Maintains Buy on AVITA Medical, Raises Price Target to $14
Benzinga · 08/19 15:10
Avita Medical price target raised to $14 from $12 at TD Cowen
TipRanks · 08/19 12:55
Avita Medical Is Maintained at Buy by BTIG
Dow Jones · 08/19 12:39
BTIG Maintains Buy on AVITA Medical, Raises Price Target to $11
Benzinga · 08/19 12:29
Avita Medical price target raised to $11 from $7 at BTIG
TipRanks · 08/19 12:15
More
Webull provides a variety of real-time RCEL stock news. You can receive the latest news about Avita Medical Inc through multiple platforms. This information may help you make smarter investment decisions.
About RCEL
AVITA Medical, Inc. is a therapeutic acute wound care company. The Company solutions are designed to optimize wound healing, accelerate patient recovery, and improve clinical and economic outcomes across the continuum of acute wound management. Its technologies address critical healing needs arising from burns, traumatic injuries, and surgical repairs, through a portfolio and complementary products that support wound bed preparation, definitive closure, and recovery. Its portfolio includes RECELL and two complementary wound care products, PermeaDerm and Cohealyx. Its RECELL technology platform is an autologous cell harvesting technology that enables clinicians to create a suspension of a patient's own skin cells, called Spray-On Skin, at the point of care. Its PermeaDerm is a biosynthetic wound matrix that manufactures, markets, and distributes in the United States, under multi-year agreements with Stedical.